Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation
- Resource Type
- Authors
- Erika J. Martin; Melinda E Nolte; Bassem M. Mohammed; Marisa Ninivaggi; John C. Barrett; Emily K. Waters; Janice Kuhn; Donald F. Brophy; Mirella Ezban
- Source
- Haemophilia. 24:815-822
- Subject
- congenital, hereditary, and neonatal diseases and abnormalities
Coefficient of variation
030204 cardiovascular system & hematology
Pharmacology
Hemophilia A
Thrombin generation
Factor XIa
Factor IXa
03 medical and health sciences
Tissue factor
0302 clinical medicine
hemic and lymphatic diseases
Humans
Medicine
In patient
030212 general & internal medicine
Genetics (clinical)
Factor VIII
business.industry
Chromogenic
Thrombin
Hematology
General Medicine
Assay sensitivity
Turoctocog alfa
business
- Language
- ISSN
- 1351-8216
INTRODUCTION The thrombin generation assay (TGA) can be used to monitor factor replacement therapy in patients with haemophilia. The TGA assay is typically performed using tissue factor as the reaction activator; however, activating with FIXa or FXIa can enhance assay sensitivity when FVIII